Ceribell, Inc.: insider trades · United States · SEC (Form 4)

About Ceribell, Inc.

Ceribell, Inc. is a US-listed medical technology company traded on the Nasdaq in the United States under the ticker CBLL. The company focuses on acute neurology, with a product platform designed to improve the diagnosis and management of patients with serious neurological conditions, especially seizure detection in hospital settings. Ceribell was founded in 2014 as Brain Stethoscope, Inc., changed its name to CeriBell, Inc. in 2015, and is headquartered in Sunnyvale, California. The business began commercial sales in 2018 after obtaining key FDA 510(k) clearances for its core hardware and software platform. At the center of the franchise is the Ceribell System, a rapid-deployment EEG solution intended for bedside use in acute care. The portfolio includes disposable or wearable headbands, a recorder, a cloud-enabled portal, and the Clarity algorithm, which supports seizure detection and signal interpretation. Ceribell is increasingly positioning itself as a platform company rather than a single-product vendor. Recent development work has broadened the addressable market to include neonatal and pediatric patients, while new applications are being pursued in delirium monitoring and large-vessel occlusion (LVO) stroke detection. The company therefore combines product revenue with subscription/software revenue, which is strategically important for long-term margin expansion and recurring cash flows. From a competitive standpoint, Ceribell occupies a specialized niche in a market where speed, ease of deployment, and clinical usability matter more than broad general-purpose features. Its differentiation lies in an integrated system that can be deployed across a range of hospital environments, from major academic centers to community hospitals. According to the latest annual report, the Ceribell System had been adopted by more than 600 hospitals as of year-end 2025, indicating meaningful commercial traction but still plenty of room for broader penetration. Recent news has been favorable on both the commercial and regulatory fronts. Ceribell reported full-year 2025 revenue of $89.1 million, followed by first-quarter 2026 revenue of $26.5 million, up 29% year over year, with 680 active accounts at the end of the quarter. The company also announced FDA milestones including clearance for neonatal use of Clarity, FDA clearance for a delirium monitoring solution, and Breakthrough Device Designation for its LVO stroke detection and monitoring program. Management also highlighted supportive CMS reimbursement developments related to the delirium solution, which could further improve adoption economics if finalized. For international investors, Ceribell stands out as a high-growth, specialty medtech name on the Nasdaq in the United States, with a compelling innovation-led story, but one that remains dependent on clinical adoption, reimbursement pathways, and continued regulatory execution.